Senior Director
Syndax
Senior Director
Syndax
Biopharmaceutical company developing oncology therapies
Syndax Pharmaceuticals is looking for a Senior Director, Alliance Management
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
The Role:
Responsible for managing, coordinating, and optimizing the alliances among Syndax and our strategic partners, contributing to the definition and development of the Alliance Management function at Syndax, and helping to evaluate and advise on key aspects of potential future alliances or partnered programs.
The ideal candidate will be a hands-on professional with strong partnering and alliance management experience who will drive management, execution, and potential extension of Syndax’s partnerships. This is a high-profile position with significant exposure across the organization, directly reporting to the SVP, Business Development, and tasked with developing the strategy and continued management of future partnerships.
Key Responsibilities:
Desired Experience/Education and Personal Attributes:
Location: Syndax’s corporate office is in New York, NY.
Syndax offers a total compensation and rewards package that is among the most competitive in the industry. Base pay is just one element of our package and is determined within a range based on several factors including market data, experience, qualifications, demonstrated skills, relevant education or training, travel requirements and internal equity. Our overall package also includes an equity offering, annual target bonuses, and an outstanding benefits program. The anticipated annualized salary range for this role is $270,000 - $290,000.
About Syndax:
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor for R/R acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus-host disease. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Pharmaceuticals is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.
#LI-Remote
Syndax Pharmaceuticals focuses on developing therapies for cancer. Its work centers on researching, testing through clinical trials, and commercializing cancer drugs, with an emphasis on difficult-to-treat cancers such as HR+ HER2- breast cancer. The company’s lead asset is Entinostat, which is being studied in combination with Exemestane for HR+ HER2- breast cancer; results from these trials will influence its growth and market position. Syndax funds its R&D and operations through capital raises and potential licensing or partnerships, and generates revenue by selling approved medicines. Its goal is to bring new cancer treatments to patients who have limited options by advancing promising oncology therapies and securing successful regulatory approvals and partnerships to scale those therapies.
Explore more opportunities at Syndax